as a catalyst for the rapid transmission of SARS-CoV-2, and potentially TB, in this population. Improving screening processes and living conditions and implementing routine vaccination strategies for this population may prevent future infectious disease outbreaks.

As the COVID-19 pandemic continues, care for patients with TB may be compromised as additional strains are placed on essential services. The 4 cases we report highlight a serious public health issue. Precautionary measures must be undertaken to be vigilant of an epidemic within the ongoing pandemic—TB. To ensure that care is not compromised, clinicians treating these at-risk populations should be aware of possible co-infection with M. tuberculosis and SARS-CoV-2 in patients with atypical radiographic features of COVID-19.

About the Author
Dr. Tham is an infectious diseases senior resident in the Department of Medicine at the National University Hospital of Singapore. His research interests include virology and public health.

References

Address for correspondence: Gabriel Yan, Division of Infectious Diseases, Department of Medicine, National University Health System, NUHS Tower Block, 1E Kent Ridge Rd, 119228, Singapore; email: gabriel_zherong_yan@nuhs.edu.sg

Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020

Amy K. Feehan, Daniel Fort, Julia Garcia-Diaz, Eboni G. Price-Haywood, Cruz Velasco, Eric Sapp, Dawn Pevey, Leonardo Seoane

Author affiliations: Ochsner Clinic Foundation, New Orleans, Louisiana, USA (A.K. Feehan, D. Fort, J. Garcia-Diaz, E.G. Price-Haywood, C. Velasco, D. Pevey, L. Seoane); University of Queensland Ochsner Clinical School, New Orleans (A.K. Feehan, J. Garcia-Diaz, E.G. Price-Haywood, L. Seoane); Public Democracy, Arlington, Virginia, USA (E. Sapp); Louisiana State University Health Science Center–Shreveport, Shreveport, Louisiana, USA (L. Seoane)

DOI: https://doi.org/10.3201/eid2611.203029

Seroprevalence studies around the world have estimated the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to range from 1.79% (1) in Boise, Idaho, USA, to 25% in Breves, Brazil (P. Hallal, unpub. data, https://doi.org/10.1101/2020.05.30.20117531). Coronavirus disease (COVID-19) has also been reported to disproportionately affect Black patients, but we do not know the infection fatality ratio (IFR), which requires knowing how many persons are at risk (i.e., infected). We estimated SARS-CoV-2 infections in Orleans and Jefferson Parishes, Louisiana, USA, and determined the COVID-19–related IFR by race.

The protocol was approved by the Ochsner Clinic Foundation Institutional Review Board (New Orleans, LA, USA) and designed to enroll and test up to 3,000 persons at 10 sites during May 9–15, 2020. To recruit a representative sample for this high-throughput method, a novel 2-step system developed by Public Democracy (https://www.publicdemocracy.io) considered >50 characteristics, including social determinants of health and US Census population

Using a novel recruitment method and paired molecular and antibody testing for severe acute respiratory syndrome coronavirus 2 infection, we determined seroprevalence in a racially diverse municipality in Louisiana, USA. Infections were highly variable by race/ethnicity. Overall census-weighted seroprevalence was 6.9%, and the calculated infection fatality ratio was 1.61%.
data, to establish a pool of potential participants reflective of the demographics of the parishes, from which a randomized subset of 150,000 was selected. Of these, >25,000 volunteers were recruited through dynamic, cross-device digital advertisements, supplemented by television advertisements and a call-in number to register (Appendix, https://wwwnc.cdc.gov/EID/article/26/11/20-3029-App1.pdf). This volunteer pool was stratified by the same attributes and then randomly issued a text message inviting them to private testing locations. Invitations were adjusted daily on the basis of response rates to achieve a representative sample. Volunteers checked in with a digital code to discourage unsolicited walk-ins. We did not turn uninformed persons away but excluded them from analysis if they did not fit criteria. Housemates of participants (n = 234) or persons from ineligible ZIP codes (n = 34) were excluded. Six people withdrew consent. All study materials were created in English, Spanish, and Vietnamese. Participants were offered free transportation if needed. Verbal consent was electronically documented, and participants were asked a short list of questions followed by a blood draw and nasopharyngeal swab.

Tests approved by the US Food and Drug Administration’s Emergency Use Authorization were used. Real-time reverse transcription PCR tests of nasopharyngeal swabs were performed on the Abbott m2000 RealTime System (Abbott, https://www.abbott.com) and qualitative IgG blood tests on the ARCHITECT i2000SR (Abbott). The IgG test meets criteria described by the Centers for Disease Control and Prevention as yielding high positive predictive value, which was validated by a laboratory at Ochsner Health and others (1,2). Study participants for whom either or both tests were positive were considered to be infected with SARS-CoV-2.

US Census values, weighted by race and parish of residence, were divided by the total sample for exposure (a PCR-positive test, an IgG-positive test, or both), point prevalence (PCR-positive only), and seroprevalence (IgG-positive tests regardless of PCR test result). The positive-testing population included persons with early-stage infections (PCR-positive only) and persons recovering (PCR-positive and IgG-positive) and recovered (IgG-positive only). Early-stage infections were excluded from IFR estimation because their outcomes would not yet be registered as deaths. Therefore, weighted seroprevalence was used to calculate persons presumed to be recovered (3). IFR was calculated by dividing cumulative deaths by race (4) by the number

### Table. Prevalence of SARS-CoV-2 infection and COVID-19–related IFR after 7 weeks of an active stay-at-home order, by race/ethnicity, 10 sites in Orleans and Jefferson Parishes, Louisiana, USA, May 9–15, 2020*

<table>
<thead>
<tr>
<th>Value</th>
<th>Total</th>
<th>White</th>
<th>Black</th>
<th>Asian</th>
<th>Native American</th>
<th>Pacific Islander</th>
<th>Multiracial or other</th>
<th>Hispanic†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive, no./total no. (%)</td>
<td><strong>183/2,640</strong></td>
<td><strong>79/1,607</strong></td>
<td><strong>90/828</strong></td>
<td><strong>9/130</strong></td>
<td><strong>0/14</strong></td>
<td><strong>0/3</strong></td>
<td><strong>5/58</strong></td>
<td><strong>18/293</strong></td>
</tr>
<tr>
<td><strong>Orleans/Jefferson Parish residents, no. (%)</strong></td>
<td><strong>825,057</strong></td>
<td><strong>419,800</strong></td>
<td><strong>356,925</strong></td>
<td><strong>29,740</strong></td>
<td><strong>4,088</strong></td>
<td><strong>495</strong></td>
<td><strong>14,009</strong></td>
<td><strong>86,289</strong></td>
</tr>
<tr>
<td><strong>Unadjusted exposure‡</strong></td>
<td><strong>6.9</strong></td>
<td><strong>6.0–8.0</strong></td>
<td><strong>3.9–6.1</strong></td>
<td><strong>8.8–13.2</strong></td>
<td><strong>3.2–12.7</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td><strong>8.6</strong></td>
</tr>
<tr>
<td><strong>Weighted exposure§</strong></td>
<td><strong>7.6</strong></td>
<td><strong>7.5–7.9</strong></td>
<td><strong>5.8–5.9</strong></td>
<td><strong>10.2–10.4</strong></td>
<td><strong>6.1–6.7</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td><strong>9.4</strong></td>
</tr>
<tr>
<td><strong>Weighted point prevalence¶</strong></td>
<td><strong>1.0</strong></td>
<td><strong>0.6–1.3</strong></td>
<td><strong>0.8–1.9</strong></td>
<td><strong>0–1.0</strong></td>
<td><strong>0–2.6</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td><strong>2.2</strong></td>
</tr>
<tr>
<td><strong>Weighted seroprevalence#</strong></td>
<td><strong>6.9</strong></td>
<td><strong>6.8–6.9</strong></td>
<td><strong>4.4–4.6</strong></td>
<td><strong>9.7–9.9</strong></td>
<td><strong>5.2–5.7</strong></td>
<td><strong>0</strong></td>
<td><strong>0</strong></td>
<td><strong>2.2</strong></td>
</tr>
<tr>
<td><strong>No. presumed recovered</strong></td>
<td><strong>56,578</strong></td>
<td><strong>18,975</strong></td>
<td><strong>34,973</strong></td>
<td><strong>1,629</strong></td>
<td><strong>–</strong></td>
<td><strong>–</strong></td>
<td><strong>1,001</strong></td>
<td><strong>4,582</strong></td>
</tr>
<tr>
<td><strong>No. deaths as of May 16, 2020</strong></td>
<td><strong>925</strong></td>
<td><strong>299</strong></td>
<td><strong>600</strong></td>
<td><strong>10</strong></td>
<td><strong>0</strong></td>
<td><strong>2</strong></td>
<td><strong>14</strong></td>
<td><strong>Unknown</strong></td>
</tr>
<tr>
<td><strong>IFR††</strong></td>
<td><strong>1.61</strong></td>
<td><strong>1.5–1.7</strong></td>
<td><strong>1.6–1.7</strong></td>
<td><strong>1.6–1.8</strong></td>
<td><strong>0.3–1.1</strong></td>
<td><strong>0.3–1.1</strong></td>
<td><strong>0.8–2.3</strong></td>
<td><strong>–</strong></td>
</tr>
</tbody>
</table>

**Values are % (95% CI) except as indicated. The 2018 population estimates and deaths by race reported by the Louisiana Department of Public Health (4). Deaths are deemed to be COVID-19–related and have an associated confirmed PCR-positive test. Probable COVID-19 deaths without a positive PCR test were not included in these counts. By May 16, a total of 13,866 state-aggregated, confirmed cases had been reported in both parishes. COVID-19, coronavirus disease; IFR, infection fatality ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; –, calculated value would be unreliable given low sample.**

†Hispanic ethnicity is a separate analysis and numbers were not subtracted from race. Hispanic deaths were not being reported as of May 16, 2020 (4).

‡Percentage of the sample with a PCR-positive test, an IgG-positive test, or both.

§Census-weighted percentage of a PCR-positive test, an IgG-positive test, or both calculated to match 2018 racial demographics by parish and then combined.

¶Census-weighted percentage of PCR-positive and IgG-positive tests calculated to match 2018 racial demographics by parish and then combined.

#Census-weighted percentage of IgG-positive tests calculated to match 2018 racial demographics by parish and then combined.

**Number of residents multiplied by weighted seroprevalence (IgG-positive tests).

††IFR equals the number of deaths per number of persons presumed recovered from SARS-CoV-2 infection plus deaths.

‡‡Significantly lower than White (p = 0.0034), Black (p = 0.0013), and multiracial or other (p = 0.0467) persons.
of persons presumed to be recovered. Methodology and symptoms observed have been described elsewhere (A. Feehan, unpub. data, https://ssrn.com/abstract=3633166).

Among the 2,640 persons in the sample, 63.5% were female and 60.9% were White; average age was 50.6 years, and average household size was 2.55 persons. Among the 183 participants who tested positive, 49% were Black. The unadjusted exposure rate of SARS-CoV-2 in the sample population was 6.9% (7.8%, census-weighted); 0.9% were positive for active viral shedding but had no detectable antibody. By race, seroprevalence was highest (9.8%) in Black participants, followed by multiracial (7.1%),
Asian (5.5%), and White (4.5%) participants. Hispanic participants had 5.3% seroprevalence. We multiplied 2018 population estimates by weighted seroprevalence to generate the number of persons presumed to be recovered (Table). Reported deaths (4) were divided by number of persons presumed to be recovered plus deaths to calculate the IFR, which was 1.61% overall. The IFR was statistically similar for White (1.55%), Black (1.69%), and multiracial (1.38%) persons but was significantly lower for Asian persons (0.61%). No COVID-19–related data on Hispanic persons were collected by the Louisiana Department of Public Health during the study period.

The prevalence of viral shedding (PCR-positive) and overall SARS-CoV-2 exposure (PCR-positive, IgG-positive, or both) were listed and mapped by ZIP code across the 2 parishes (Figure). Prevalence was highly variable across the map and in some areas exceeded 20%.

Prevalence studies help to understand infection spread, especially when testing resources are limited. Our study found the overall SARS-CoV-2 exposure rate in this area to be 7.8% and confirmed a recent report of overrepresentation of Black persons with COVID-19 in the New Orleans area (5). Multiracial, Hispanic, and Asian persons also had higher seroprevalence than White persons. The overall IFR was 1.63%, which is higher than IFRs found in other seroprevalence studies (0.5%–1.2%) (6; M. Emmenegger, unpub. data, https://doi.org/10.1101/2020.05.31.2018554; P. Hallal, unpub. data, https://doi.org/10.1101/2020.05.30.20117531). The similar IFR among most racial groups indicates that viral spread at least partially explains the increased number of deaths among minority populations.

Acknowledgments
The authors would like to especially thank the laboratories at the Ochsner Medical Center Jefferson Highway Campus for testing and keeping track of research samples; Dan Nichols; Sarah Roberts and Gina Mmahafor clinical site management; Samantha Bright, Lyndsey Buckner-Baiamonte, and Ansley Hammons for research site management; Emily Arata for liaising with public leaders; and countless research coordinators, clinical staff, marketing personnel, medical students, and Epic and IT staff for making site testing possible. The Ochsner Health Market Planning and Analysis team designed the maps in Figure. The authors thank Kathleen McFadden for her thorough editing and Mark Roberts for his review and the Ochsner Language Services Department for helping to increase inclusivity. We would also like to acknowledge the New Orleans Mayor’s Office, City of New Orleans Office of Public Health, and the New Orleans City Council, especially council members Helena Moreno and Jason Williams for filming a public service announcement to help recruit participants. We also thank Jefferson Parish President Cynthia Lee Sheng and Parish Council for their support.

We thank George Hutter and ReNOLA for their financial support.

About the Author
Dr. Feehan is a research scientist at the Ochsner Clinic Foundation’s Infectious Disease Clinical Research Department. Her research focuses on the gut microbiome as a treatment modality for neurologic disease, but more immediately on the SARS-CoV-2 pandemic that has greatly impacted the New Orleans area.

References

Address for correspondence: Amy K. Feehan, Ochsner Health, 1st floor AT, Infectious Diseases, 1514 Jefferson Hwy, New Orleans, LA 70121, USA; email: amy.feehan@ochsner.org